Mitiglinide

Mitiglinide

Systematic (IUPAC) name
(2S)-2-benzyl-4-[(3aR,7aS)-octahydro-2H-isoindol- 2-yl]-4-oxobutanoic acid
Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy cat.	?
Legal status	?
Routes	oral
Identifiers
CAS number	207844-01-7^N
ATC code	A10BX08
PubChem	CID 121891
DrugBank	DB01252
ChemSpider	108739^Y
UNII	D86I0XLB13^Y
KEGG	D01854^Y
ChEMBL	CHEMBL471498^Y
Chemical data
Formula	C₁₉H₂₅N O₃
Mol. mass	315.41 g/mol
SMILES	eMolecules & PubChem
InChI InChI=1S/C19H25NO3/c21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14/h1-3,6-7,15-17H,4-5,8-13H2,(H,22,23)/t15-,16+,17-/m0/s1^Y Key:WPGGHFDDFPHPOB-BBWFWOEESA-N^Y
N(what is this?) (verify)

Mitiglinide (INN, trade name Glufast) is a drug for the treatment of type 2 diabetes.^[1]

Mitiglinide belongs to the meglitinide class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.

1 Pharmacology
2 Dosage
3 References
4 External links

Pharmacology

Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) K(ATP) channels in pancreatic beta-cells.

Dosage

Mitiglinide is delivered in tablet form.

References

^ Malaisse WJ (October 2008). "Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients". Expert Opin Pharmacother 9 (15): 2691–8. doi:10.1517/14656566.9.15.2691. PMID 18803455. http://www.informapharmascience.com/doi/abs/10.1517/14656566.9.15.2691.

External links

Elixir Pharmaceuticals - website of the U.S. rights holder for mitiglinide.

Oral anti-diabetic drugs and Insulin analogs (A10)

Insulin

Sensitizers

Biguanides	Metformin^# • Buformin^‡ • Phenformin^‡

TZDs (PPAR)	Pioglitazone • Rivoglitazone^† • Rosiglitazone • Troglitazone^‡

Dual PPAR agonist	Aleglitazar^† • Muraglitazar^§ • Tesaglitazar^§

Secretagogues

K+ ATP

Sulfonylureas	1st generation: Acetohexamide • Carbutamide • Chlorpropamide • Tolbutamide • Tolazamide 2nd generation: Glibenclamide (Glyburide)^# • Glipizide • Gliquidone • Glyclopyramide • Glimepiride • Gliclazide •

Meglitinides/"glinides"	Nateglinide • Repaglinide • Mitiglinide

GLP-1 analogs

Exenatide • Liraglutide • Taspoglutide^† • Albiglutide^† • Lixisenatide

DPP-4 inhibitors

Alogliptin^† • Linagliptin • Saxagliptin • Sitagliptin • Vildagliptin

Analogs/other insulins

fast-acting (Insulin lispro • Insulin aspart • Insulin glulisine) • short-acting (Regular insulin) • long-acting (Insulin glargine • Insulin detemir • NPH insulin) • ultra-long-acting (Insulin degludec^†) • inhalable Exubera^‡

Other

Alpha-glucosidase inhibitors	Acarbose • Miglitol • Voglibose

Amylin analog	Pramlintide

SGLT2 inhibitors	Canagliflozin^† • Dapagliflozin^† • Remogliflozin^§ • Sergliflozin^§

Other	Benfluorex^‡ • Tolrestat^‡

^#WHO-EM. ^‡Withdrawn from market. Clinical trials: ^†Phase III. ^§Never to phase III

M: END

anat/phys/devp/horm

noco(d)/cong/tumr, sysi/epon

proc, drug (A10/H1/H2/H3/H5)

Mitiglinide

Contents

Pharmacology

Dosage

References

External links